Global Mitochondrial-based Therapeutics Market Research Report 2024

Publication ID:

PB507248948

Publication Date:

July 3, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Mitochondria are therefore vital for normal cellular function, including听intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.
The global Mitochondrial-based Therapeutics market was valued at US$ 379 million in 2023 and is anticipated to reach US$ 651.3 million by 2030, witnessing a CAGR of 7.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Mitochondrial-based Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mitochondrial-based Therapeutics.
Report Scope
The Mitochondrial-based Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Mitochondrial-based Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mitochondrial-based Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Reneo Pharmaceutical
Pfizer Inc.
Norvartis AG
Takeda Pharmaceuticals
Amgen Inc.
NeuroVive Pharmaceutical AB
Entogene AG
Stealth Biotherapeutics
Ixchel Pharma
Reata Pharmaceuticals
Segment by Type
Oral
Intravenous
Segment by Application
Mitochondrial Myopathy
Leber鈥檚 heredity Optic Neuropathy
Leigh Syndrome
Mitochondrial DNA Depletion Syndrome
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mitochondrial-based Therapeutics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mitochondrial-based Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Intravenous
1.3 Market by Application
1.3.1 Global Mitochondrial-based Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Mitochondrial Myopathy
1.3.3 Leber鈥檚 heredity Optic Neuropathy
1.3.4 Leigh Syndrome
1.3.5 Mitochondrial DNA Depletion Syndrome
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mitochondrial-based Therapeutics Market Perspective (2019-2030)
2.2 Mitochondrial-based Therapeutics Growth Trends by Region
2.2.1 Global Mitochondrial-based Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Mitochondrial-based Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Mitochondrial-based Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Mitochondrial-based Therapeutics Market Dynamics
2.3.1 Mitochondrial-based Therapeutics Industry Trends
2.3.2 Mitochondrial-based Therapeutics Market Drivers
2.3.3 Mitochondrial-based Therapeutics Market Challenges
2.3.4 Mitochondrial-based Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mitochondrial-based Therapeutics Players by Revenue
3.1.1 Global Top Mitochondrial-based Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Mitochondrial-based Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Mitochondrial-based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Mitochondrial-based Therapeutics Revenue
3.4 Global Mitochondrial-based Therapeutics Market Concentration Ratio
3.4.1 Global Mitochondrial-based Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mitochondrial-based Therapeutics Revenue in 2023
3.5 Mitochondrial-based Therapeutics Key Players Head office and Area Served
3.6 Key Players Mitochondrial-based Therapeutics Product Solution and Service
3.7 Date of Enter into Mitochondrial-based Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Mitochondrial-based Therapeutics Breakdown Data by Type
4.1 Global Mitochondrial-based Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Mitochondrial-based Therapeutics Forecasted Market Size by Type (2025-2030)
5 Mitochondrial-based Therapeutics Breakdown Data by Application
5.1 Global Mitochondrial-based Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Mitochondrial-based Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Mitochondrial-based Therapeutics Market Size (2019-2030)
6.2 North America Mitochondrial-based Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Mitochondrial-based Therapeutics Market Size by Country (2019-2024)
6.4 North America Mitochondrial-based Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mitochondrial-based Therapeutics Market Size (2019-2030)
7.2 Europe Mitochondrial-based Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Mitochondrial-based Therapeutics Market Size by Country (2019-2024)
7.4 Europe Mitochondrial-based Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mitochondrial-based Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Mitochondrial-based Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mitochondrial-based Therapeutics Market Size (2019-2030)
9.2 Latin America Mitochondrial-based Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Mitochondrial-based Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Mitochondrial-based Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mitochondrial-based Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Mitochondrial-based Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Reneo Pharmaceutical
11.1.1 Reneo Pharmaceutical Company Detail
11.1.2 Reneo Pharmaceutical Business Overview
11.1.3 Reneo Pharmaceutical Mitochondrial-based Therapeutics Introduction
11.1.4 Reneo Pharmaceutical Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.1.5 Reneo Pharmaceutical Recent Development
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Detail
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Mitochondrial-based Therapeutics Introduction
11.2.4 Pfizer Inc. Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.2.5 Pfizer Inc. Recent Development
11.3 Norvartis AG
11.3.1 Norvartis AG Company Detail
11.3.2 Norvartis AG Business Overview
11.3.3 Norvartis AG Mitochondrial-based Therapeutics Introduction
11.3.4 Norvartis AG Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.3.5 Norvartis AG Recent Development
11.4 Takeda Pharmaceuticals
11.4.1 Takeda Pharmaceuticals Company Detail
11.4.2 Takeda Pharmaceuticals Business Overview
11.4.3 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Introduction
11.4.4 Takeda Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.4.5 Takeda Pharmaceuticals Recent Development
11.5 Amgen Inc.
11.5.1 Amgen Inc. Company Detail
11.5.2 Amgen Inc. Business Overview
11.5.3 Amgen Inc. Mitochondrial-based Therapeutics Introduction
11.5.4 Amgen Inc. Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.5.5 Amgen Inc. Recent Development
11.6 NeuroVive Pharmaceutical AB
11.6.1 NeuroVive Pharmaceutical AB Company Detail
11.6.2 NeuroVive Pharmaceutical AB Business Overview
11.6.3 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Introduction
11.6.4 NeuroVive Pharmaceutical AB Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.6.5 NeuroVive Pharmaceutical AB Recent Development
11.7 Entogene AG
11.7.1 Entogene AG Company Detail
11.7.2 Entogene AG Business Overview
11.7.3 Entogene AG Mitochondrial-based Therapeutics Introduction
11.7.4 Entogene AG Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.7.5 Entogene AG Recent Development
11.8 Stealth Biotherapeutics
11.8.1 Stealth Biotherapeutics Company Detail
11.8.2 Stealth Biotherapeutics Business Overview
11.8.3 Stealth Biotherapeutics Mitochondrial-based Therapeutics Introduction
11.8.4 Stealth Biotherapeutics Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.8.5 Stealth Biotherapeutics Recent Development
11.9 Ixchel Pharma
11.9.1 Ixchel Pharma Company Detail
11.9.2 Ixchel Pharma Business Overview
11.9.3 Ixchel Pharma Mitochondrial-based Therapeutics Introduction
11.9.4 Ixchel Pharma Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.9.5 Ixchel Pharma Recent Development
11.10 Reata Pharmaceuticals
11.10.1 Reata Pharmaceuticals Company Detail
11.10.2 Reata Pharmaceuticals Business Overview
11.10.3 Reata Pharmaceuticals Mitochondrial-based Therapeutics Introduction
11.10.4 Reata Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2019-2024)
11.10.5 Reata Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Reneo Pharmaceutical
Pfizer Inc.
Norvartis AG
Takeda Pharmaceuticals
Amgen Inc.
NeuroVive Pharmaceutical AB
Entogene AG
Stealth Biotherapeutics
Ixchel Pharma
Reata Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂